Histochrome Attenuates Myocardial Ischemia-Reperfusion Injury by Inhibiting Ferroptosis-Induced Cardiomyocyte Death

• Published in: Antioxidants Vol. 10; no. 10; p. 1624
• Main Authors: Hwang, Ji-Won, Park, Jae-Hyun, Park, Bong-Woo, Kim, Hyeok, Kim, Jin-Ju, Sim, Woo-Sup, Mishchenko, Natalia P., Fedoreyev, Sergey A., Vasileva, Elena A., Ban, Kiwon, Park, Hun-Jun, Baek, Sang-Hong
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 15-10-2021; MDPI
• Subjects: anti-ferroptosis; Antibodies; Antioxidants; Apoptosis; Blood vessels; Cardiac function; Cardiomyocytes; cardioprotection; Catheters; Cell death; Echocardiography; Ferroptosis; Fibrosis; Glutathione peroxidase; Heart; Heart attacks; histochrome; Injection; Intracellular; Intravenous administration; Iron; iron-chelating; Ischemia; ischemia-reperfusion injury; Laboratory animals; Lipid peroxidation; Mitochondria; Myocardial ischemia; Myocardium; Neonates; Ostomy; Reactive oxygen species; Reperfusion; Surgery; Veins & arteries; United States > US; Russia
• ISSN: 2076-3921; 2076-3921
• DOI: 10.3390/antiox10101624

Reactive oxygen species (ROS) and intracellular iron levels are critical modulators of lipid peroxidation that trigger iron-dependent non-apoptotic ferroptosis in myocardial ischemia-reperfusion (I/R) injury. Histochrome (HC), with a potent antioxidant moiety and iron-chelating capacity, is now available in clinical practice. However, limited data are available about the protective effects of HC on ferroptotic cell death in myocardial I/R injury. In this study, we investigated whether the intravenous administration of HC (1 mg/kg) prior to reperfusion could decrease myocardial damage by reducing ferroptosis. Rats undergoing 60 min of ischemia and reperfusion were randomly divided into three groups as follows: (1) Sham, (2) I/R control, and (3) I/R + HC. Serial echocardiography up to four weeks after I/R injury showed that intravenous injection of HC significantly improved cardiac function compared to the I/R controls. In addition, the hearts of rats who received intravenous injection of HC exhibited significantly lower cardiac fibrosis and higher capillary density. HC treatment decreased intracellular and mitochondrial ROS levels by upregulating the expression of nuclear factor erythroid 2-related factor (Nrf2) and its downstream genes. HC also inhibited erastin- and RSL3-induced ferroptosis in rat neonatal cardiomyocytes by maintaining the intracellular glutathione level and through upregulated activity of glutathione peroxidase 4. These findings suggest that early intervention with HC before reperfusion rescued myocardium from I/R injury by preventing ferroptotic cell death. Therefore, HC is a promising therapeutic option to provide secondary cardioprotection in patients who undergo coronary reperfusion therapy.